Billiontoone, Inc. (NASDAQ:BLLN) Receives $137.83 Consensus PT from Analysts

Shares of Billiontoone, Inc. (NASDAQ:BLLN) have earned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $137.8333.

BLLN has been the subject of a number of recent analyst reports. Stifel Nicolaus assumed coverage on Billiontoone in a research report on Monday, December 1st. They set a “buy” rating and a $145.00 target price for the company. Jefferies Financial Group began coverage on shares of Billiontoone in a research report on Monday, December 1st. They set a “hold” rating and a $117.00 price objective for the company. Zacks Research upgraded shares of Billiontoone to a “hold” rating in a research note on Tuesday, December 2nd. Piper Sandler restated an “overweight” rating on shares of Billiontoone in a research report on Wednesday, December 10th. Finally, William Blair started coverage on shares of Billiontoone in a research report on Monday, December 1st. They set an “outperform” rating on the stock.

Billiontoone Stock Performance

Shares of NASDAQ BLLN opened at $85.09 on Friday. The company has a market cap of $3.89 billion and a PE ratio of 850.90. Billiontoone has a 1-year low of $81.51 and a 1-year high of $138.70.

Billiontoone (NASDAQ:BLLN) last released its quarterly earnings results on Tuesday, December 9th. The company reported $0.10 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.06). The company had revenue of $83.52 million for the quarter, compared to analyst estimates of $82.86 million.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.